| |
|
|
|
|
|
|
|||
|
Blood, Vol. 95 No. 12 (June 15), 2000:
pp. 3964-3969
PHAGOCYTES
From the Institute of Pathology, University of Cologne, Cologne,
Germany; and the Division of Basic Sciences, National Cancer Institute,
Frederick Cancer Research and Development Center, Frederick, MD.
Hepatocyte growth factor (HGF) is a pluripotent cytokine
with mitogenic, motogenic, and morphogenic activity for mainly
epithelial and endothelial target cells. We previously demonstrated
that the specific HGF receptor, MET, is induced in stimulated
peripheral blood monocytes. In this study, we analyzed the functional
consequences of MET activation in primary cultures of peripheral blood
monocytes from healthy donors. After stimulation of
MET-expressing monocytes with recombinant HGF, the gene-expression
profile of peripheral blood mononuclear cells and monocytes was
significantly modulated, especially with regard to genes involved in
cell movement. After stimulation of primary cultured monocytes with
HGF, invasion assays showed a significantly increased matrigel invasion
rate that was completely abolished by neutralizing antibodies to HGF.
The HGF-activated invasiveness and the altered
gene-expression profile suggest a proinflammatory role for HGF
stimulation of monocytes and support the hypothesis that the HGF/MET
signaling system plays an important part in the activation of the
nonspecific cellular inflammatory response.
(Blood. 2000;95:3964-3969)
Hepatocyte growth factor (HGF) is a multifunctional
cytokine with pleiotropic effects. It exerts mitogenic activity on a
wide range of endothelial and epithelial cells,1,2
Furthermore, it induces a motogenic and morphogenic program in a
variety of cell types, such as hepatocytes and kidney epithelial
cells.3-5 All the different effects of HGF are mediated
through its specific receptor, MET, a heterodimeric transmembranous
tyrosine kinase.6 After ligand-induced activation of MET,
different intracellular signal-transduction pathways are activated
through a C-terminal cytoplasmic multifunctional docking
site.7
The broad activity of HGF and its impact on many physiologic and
pathological processes is reflected by MET expression in a variety of
organs and cell types. HGF/MET signaling is involved in organ
regeneration, as has been shown in the liver and kidney,8,9 and in embryogenesis.10,11 HGF is neurotrophic for central nervous system neurons,12,13 is also expressed in several
hematopoietic cell lines,14,15 and costimulates
proliferation and differentiation of CD34-positive hematopoietic
precursor cells.16,17 In addition, HGF/MET signaling may
contribute to tumor cell invasion.18-20
HGF is highly overexpressed during necroinflammatory liver disease and
is elevated in the serum of patients with acute or chronic hepatitis,
liver cirrhosis, or hepatocellular carcinoma.21 HGF is
thought to have cytoprotective activity on hepatocytes,22 to be antifibrogenic,23 and to stimulate transmigration of
T-cell subsets from peripheral blood.24 Furthermore, HGF
expression in necroinflammatory liver disease was demonstrated in
infiltrating leukocytes by in situ hybridization (ISH) and
immunohistologic studies.25,26 In addition, increased
deposits of HGF were found along the basal lamina in inflammatory
lesions of other organs, such as the lung and kidney.27 All
these observations suggest that HGF/MET signaling is
important in necroinflammation of various organs.
We previously showed that MET expression becomes selectively induced
and functionally active in monocytes.28 In the study described here, we examined the functional role of MET expression, ie,
the induced HGF responsiveness in monocytes specifically with regard to
the inflammatory response. We found extensive modulation of the
gene-expression profile, including effects on genes involved in
directed cell movement, and a significantly increased invasiveness of
MET-expressing monocytes after stimulation with HGF.
Cell cultures and isolation of peripheral blood mononuclear cells
(PBMNC) and monocytes from peripheral blood
Immunocytologic studies
Analysis of gene expression To investigate the influence of HGF incubation on gene expression, 2 × 106 PBMNC/mL and monocytes were cultured in Teflon jars for 4 hours under standard conditions, with or without 100 ng/mL recombinant human HGF in RPMI 1640 medium supplemented with 1% FCS and 0.1% bovine serum albumin (BSA; Sigma). After the cells were harvested, total RNA was isolated with an RNeasy kit (Qiagen, Hilden, Germany). In the PBMNC, poly (A+) RNA was obtained from total RNA with an OligoTex kit (Qiagen).Matrix invasion assay A monocyte matrix invasion assay was performed by using matrigel invasion chambers with 8-µm pores (Becton Dickinson). To reduce the influence of different cytokines, growth factor-reduced matrigel preparations were used. After matrigel rehydration, the wells were filled with 100 ng/mL recombinant human HGF (750 µL) and freshly isolated monocytes were seeded onto the inserts at a density of 1.2 × 106 cells/500 µL so that the matrigel separated the cells from the HGF solution and supported a gradient. Because it was necessary to use solutions free of protease inhibitors, FCS-free Diff 1000 medium (Biochrom, Berlin, Germany) supplemented with 0.1% BSA was used for the assay. For control experiments, the HGF polypeptides were preincubated with 10 µg/mL of a neutralizing anti-human HGF antibody (Sigma) in test medium at room temperature for 30 minutes and washed twice with medium before the assay was performed. At 2 different time points, after 18 hours (± 3 hours because of donor variability) and 48 hours of incubation at 37°C in 5% carbon dioxide, incubation was stopped. The first time point was selected when approximately 2% of the control cell population (ie, not the HGF-stimulated cell fraction) had transmigrated. The matrigel and the cells retained on the upper side of the membrane were removed, and the transmigrated cells at the bottom side were fixed with methanol, counterstained with Mayer's hemalum and eosin, mounted with oil, and covered with a glass coverslip. Optical evaluation of adherent cells on the bottom side of the membrane was done morphometrically. When the total number of cells was low, all cells on the membrane were counted. When cell numbers were higher, only cells along standardized centered lines were counted. Only 1 type of evaluation was used in each experiment, and relative cell numbers were determined. The number of cells in the cell fraction stimulated by HGF for 18 hours was arbitrarily set at 1.
MET was moderately expressed in purified monocytes Use of a polyclonal antibody binding to the intracellular domain of MET detected expression of MET protein in monocytes (Figure 1A-D). Although cytoplasmic and membranous expression was detected in a minority of freshly isolated monocytes, the signal was increased and found in more than 50% of the monocyte fraction after activation with phytohemagglutinin (PHA) and lipopolysaccharide (LPS). As in previous experiments with PBMNC, MET was detectable only in monocytes. FACS analysis revealed that the purity of the negatively isolated monocyte preparations was greater than 90% in all cases (Figure 1E).
HGF modulated the gene-expression pattern of monocytes Freshly isolated PBMNC and monocytes derived from PBMNC were incubated with recombinant HGF [100 ng/mL] for 4 hours. After extraction of the RNA from the control and stimulated cell populations, gene expression in the 2 populations was analyzed and compared by using cDNA expression arrays. Expression analysis in monocytes revealed that 13% of the analyzed genes were modulated by HGF. Of those genes, 65% were activated and 35% were suppressed; differences in expression modulation ranged from about 1.5- to 4-fold (Figure 2, Table 1). Most of the genes that were activated by HGF are known to be inducible in monocytes.
HGF enhanced the migratory activity of MET-positive primary cultured monocytes Because many genes involved in cell migration were significantly activated by incubation of monocytes or PBMNC with HGF, we analyzed the possible influence of HGF/MET signaling on monocytic invasiveness by using primary cultured monocytes, which were previously shown to express MET. In a chemotaxis assay, monocytes from different donors showed a broad variability in response, but overall a significant chemotactic reaction in response to HGF stimulation was not demonstrated (data not shown).
In previous experiments, we showed by using ISH that
c-met transcription was induced in preactivated PBMNC treated
with PHA and LPS and that among this heterogenous cell population, MET expression was derived only from monocytes. Here, we found that MET
protein was detectable only in monocytes and especially in the
enriched, activated monocyte fraction. In addition, the percentage of
MET-expressing cells among PBMNC was comparable to that in the
monocyte-enriched cell fraction. The higher percentage of MET-positive
cells compared with results from previous ISH experiments28 likely reflects the greater sensitivity of immunohistochemical analysis
compared with ISH when the 2 assessments are used together.
Submitted July 9, 1999; accepted February 10, 2000.
Supported by grant Schi 273/3 from the Deutsche Forschungsgemeinschaft
(P.S.) and the Stiftung Rheinland-Pfalz für Innovation (P.S. and
H.P.D.) and Köln Fortune (P.S.).
Reprints: Peter Schirmacher, Institute of Pathology, University
of Cologne, Joseph-Stelzmann-Str 9, 50931 Cologne, Germany; e-mail:
peter.schirmacher{at}uni-koeln.de.
The publication costs of this
article were defrayed in part by
page charge payment. Therefore,
and solely to indicate this fact,
this article is hereby marked
"advertisement"
in accordance with 18 U.S.C.
section 1734.
1.
Zarnegar R, Michalopoulos G.
Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes.
Cancer Res.
1989;49:3314-3320
2.
Kan M, Zhang GH, Zarnegar R, et al.
Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV-40 transformed RPTE.
Biochem Biophys Res Commun.
1991;174:331-337[Medline]
[Order article via Infotrieve].
3.
Stoker M, Gherardi E, Perryman M, Grav J.
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility.
Nature.
1987;327:239-242[Medline]
[Order article via Infotrieve].
4.
Rosen EM, Goldberg ID, Kacinski BM, Buckholz T, Vinter DW.
Smooth muscle releases an epithelial cell scatter factor which binds to heparin.
In Vitro Cell Dev Biol.
1989;25:163-173[Medline]
[Order article via Infotrieve].
5.
Santos OFP, Barros EJG, Yang XM, et al.
Involvement of hepatocyte growth factor in kidney development.
Dev Biol.
1994;163:525-529[Medline]
[Order article via Infotrieve].
6.
Bottaro DP, Rubin JS, Faletto DL, et al.
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
Science.
1991;251:802-804
7.
Ponzetto C, Bardelli A, Maina F, et al.
A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor.
Mol Cell Biol.
1993;13:4600-4608
8.
Lindroos PM, Zarnegar R, Michalopoulos GK.
Hepatocyte growth factor (hepatopoietin A) rapidly increases in plasma before DNA synthesis and liver regeneration stimulated by partial hepatectomy and carbon tetrachloride administration.
Hepatology.
1991;13:743-750[Medline]
[Order article via Infotrieve].
9.
Igawa T, Matsumoto K, Kanda S, Saito Y, Nakamura T.
Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury.
Am J Physiol.
1993;265:F61-F69
10.
Schmidt C, Bladt F, Goedecke S, et al.
Scatter factor/hepatocyte growth factor is essential for liver development.
Nature.
1995;373:699-702[Medline]
[Order article via Infotrieve].
11.
Uehara Y, Minowa O, Mori C, et al.
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.
Nature.
1995;373:702-705[Medline]
[Order article via Infotrieve].
12.
Jung W, Castren E, Odenthal M, et al.
Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain.
J Cell Biol.
1994;126:485-494
13.
Honda S, Kagoshima M, Wanaka A, Tohyama M, Matsumoto K, Nakamura T.
Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor.
Mol Brain Res.
1995;32:197-210[Medline]
[Order article via Infotrieve].
14.
Nishino T, Kaise N, Sindo Y, et al.
Promyelocytic leukemia cell line, HL-60, produces human hepatocyte growth factor.
Biochem Biophys Res Commun.
1991;181:323-330[Medline]
[Order article via Infotrieve].
15.
Mizuno K, Higuchi O, Ihle JN, Nakamura T.
Hepatocyte growth factor stimulates growth of hematopoietic progenitor cells.
Biochem Biophys Res Commun.
1993;194:178-186[Medline]
[Order article via Infotrieve].
16.
Kmiecik TE, Rosen E, Vande Woude GF.
Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells.
Blood.
1992;80:2454-2457
17.
Galimi F, Bagnara GP, Bonsi L, et al.
Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemapoietic progenitors.
J Cell Biol.
1994;127:1743-1754
18.
Jeffers M, Rong S, Vande Woude GF.
Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis.
J Mol Med.
1996;74:505-513[Medline]
[Order article via Infotrieve].
19.
Tamagnone L, Comoglio PM.
Control of invasive growth by hepatocyte growth factor (HGF) and related factors.
Cytokine Growth Factor Rev.
1997;8:129-142[Medline]
[Order article via Infotrieve].
20.
Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J.
Met-HGF/SF: tumorigenesis, invasion and metastasis.
Ciba Found Symp.
1997;212:119-132[Medline]
[Order article via Infotrieve]148-154.
21.
Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T.
Serum hepatocyte growth factor levels in liver diseases: clinical implications.
Hepatology.
1995;21:106-112[Medline]
[Order article via Infotrieve].
22.
Okano J, Shiota G, Kawasaki H.
Protective action of hepatocyte growth factor for acute liver injury caused by D-galactosamine in transgenic mice.
Hepatology.
1997;26:1241-1249[Medline]
[Order article via Infotrieve].
23.
Ueki T, Kaneda Y, Tsutsui H, et al.
Hepatocyte growth factor gene therapy of liver cirrhosis in rats.
Nat Med.
1999;5:226-230[Medline]
[Order article via Infotrieve].
24.
Adams DH, Harvath L, Bottaro DP, et al.
Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells.
Proc Natl Acad Sci U S A.
1994;91:7144-7148
25.
Schirmacher P, Geerts A, Jung W, Pietrangelo A, Rogler CE, Dienes HP.
The role of Ito cells in the biosynthesis of HGF-SF in the liver. In:
Goldberg ID,Rosen EM, eds.
Hepatocyte Growth Factor (HGF-SF) and the c-Met Receptor. Basel, Switzerland: Birkhäuser Verlag; 1993:285-299.
26.
Sakaguchi H, Seki S, Tsubouchi H, Daikuhara Y, Niitani Y, Kobayashi K.
Ultrastructural location of human hepatocyte growth factor in human liver.
Hepatology.
1994;19:1157-1163[Medline]
[Order article via Infotrieve].
27.
Yoshinaga Y, Matsuno Y, Fujita S, et al.
Immunohistochemical detection of hepatocyte growth factor/scatter factor in human cancerous and inflammatory lesions of various organs.
Jpn J Cancer Res.
1993;84:1150-1158[Medline]
[Order article via Infotrieve].
28.
Beilmann M, Odenthal M, Jung W, Vande Woude GF, Dienes HP, Schirmacher P.
Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor in activated monocytes.
Blood.
1997;90:4450-4458
29.
Flo RW, Naess A, Lund-Johansen F, et al.
Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies.
J Immunol Methods.
1991;137:89-94[Medline]
[Order article via Infotrieve].
30.
Huang YS, Chan CY, Wu JC, Pai CH, Chao Y, Lee SD.
Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival.
J Hepatol.
1996;24:377-384[Medline]
[Order article via Infotrieve].
31.
Jayatilleke A, Shaw S.
Stimulation of monocyte interleukin-8 by lipid peroxidation products: a mechanism for alcohol-induced liver injury.
Alcohol.
1998;16:119-123[Medline]
[Order article via Infotrieve].
32.
Xu Y, Rojkind M, Czaja MJ.
Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat-storing cells.
Gastroenterology.
1996;110:1870-1877[Medline]
[Order article via Infotrieve].
33.
Marra F, De Franco R, Grappone C, et al.
Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration.
Am J Pathol.
1998;152:423-430[Abstract].
34.
Marra F, De Franco R, Grappone C, et al.
Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E.
J Investig Med.
1999;47:66-75[Medline]
[Order article via Infotrieve].
35.
Cowin AJ, Brosnan MP, Holmes TM, Ferguson MW.
Endogenous inflammatory response to dermal wound healing in the fetal and adult mouse.
Dev Dyn.
1998;212:385-393[Medline]
[Order article via Infotrieve].
36.
Engelhardt E, Toksoy A, Goebeler M, Debus S, Brocker EB, Gillitzer R.
Chemokines IL-8, GRO
37.
Rong S, Bodescot M, Blair D, et al.
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.
Mol Cell Biol.
1992;12:5152-5158
38.
Giordano S, Zhen Z, Medico E, Galimi F, Comoglio PM.
Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene.
Proc Natl Acad Sci U S A.
1993;90:649-653
39.
Jeffers M, Rao M, Rulong S, et al.
Hepatocyte growth factor/scatter factor-met signalling induces proliferation, migration, and morphogenesis of pancreatic oval cells.
Cell Growth Differ.
1996;7:1805-1813[Abstract].
40.
Gyetko MR, Todd RF 3rd, Wilkinson CC, Sitrin RG.
The urokinase receptor is required for human monocyte chemotaxis in vitro.
J Clin Invest.
1994;93:1380-1387.
41.
Gak E, Taylor WG, Chan AM, Rubin JS.
Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity.
FEBS Lett.
1992;17:311-313.
42.
Tynes HC, Su M, Washington K, Kerins DM, Vaughn DE, Russell WE.
Liver regeneration is delayed in urokinase-deficient mice [abstract].
Hepatology.
1997;26:373A.
43.
Jeffers M, Rong S, Vande Woude GF.
Enhanced tumorigenicity and invasion/metastasis by hepatocyte growth factor/scatter factor-Met signalling in human cells concomitant with induction of the urokinase proteolysis network.
Mol Cell Biol.
1996;16:1115-1125[Abstract].
44.
Pepper MS, Matsumoto K, Nakamura T, Orci L, Montesano R.
Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells.
J Biol Chem.
1992;267:20,493-20,496
45.
Ponzetto C, Bardelli A, Zhen Z, et al.
A multifunctional docking site mediates signalling and transformation by hepatocyte growth factor/scatter factor receptor family.
Cell.
1994;77:261-271[Medline]
[Order article via Infotrieve].
46.
Ponzetto C, Zhen Z, Audero E, et al.
Specific uncoupling of GRB2 from the MET receptor.
J Biol Chem.
1996;271:14,119-14,123
47.
Giordano S, Bardelli A, Zhen Z, Menard S, Ponzetto C, Comoglio PM.
A point mutation in the MET oncogene abrogates metastasis without affecting transformation.
Proc Natl Acad Sci U S A.
1997;94:13,868-13,872
48.
Chen Q, DeFrances MC, Zarnegar R.
Induction of met proto-oncogene (hepatocyte growth factor receptor) expression during human monocyte-macrophage differentiation.
Cell Growth Differ.
1996;7:821-832[Abstract].
49.
Tsubouchi H, Niitani Y, Hirono S, et al.
Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay.
Hepatology.
1991;13:1-5[Medline]
[Order article via Infotrieve].
50.
Zarnegar R, DeFrances MC, Kost PD, Lindroos P, Michalopoulos GK.
Expression of hepatocyte growth factor mRNA in regenerating rat liver after partial hepatectomy.
Biochem Biophys Res Commun.
1991;177:559-565[Medline]
[Order article via Infotrieve].
This article has been cited by other articles:
| ||||||||||